<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="37684">Mannose</z:chebi>-binding lectin (MBL) and Toll-like receptor (TLR) polymorphisms may influence susceptibility and manifestation of <z:e sem="disease" ids="C0041234" disease_type="Disease or Syndrome" abbrv="">Trypanosoma cruzi infection</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In northern Chile, we examined 61 asymptomatic patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0041234" disease_type="Disease or Syndrome" abbrv="">Chagas disease</z:e> (CD), 64 patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> Chagas <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> (<z:chebi fb="61" ids="32879">CCC</z:chebi>), and 45 healthy individuals </plain></SENT>
<SENT sid="2" pm="."><plain>Low-producer MBL2*B genotypes were more common in CD patients (48%) than healthy individuals (31%; adjusted odds ratio = 2.3, 95% confidence interval = 1.01-5.4, P = 0.047) but did not differ with manifestation </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast, the heterozygous Toll-like receptor 4 (TLR4)-deficiency genotype D299G/T399I occurred more frequently in asymptomatic (14.8%) than <z:chebi fb="61" ids="32879">CCC</z:chebi> patients (3.1%; P = 0.02) </plain></SENT>
<SENT sid="4" pm="."><plain>TLR1-I602S, TLR2-R753Q, TLR6-S249P, and MAL/TIRAP-S180L did not associate with CD or <z:chebi fb="61" ids="32879">CCC</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>These findings support the complement system to be involved in defense against <z:e sem="disease" ids="C0041234" disease_type="Disease or Syndrome" abbrv="">Trypanosoma cruzi infection</z:e> and indicate that curbed TLR4 activation might be beneficial in preventing <z:chebi fb="61" ids="32879">CCC</z:chebi> </plain></SENT>
</text></document>